Fig 1.
Serum concentration profiles for ABZ, ABZSO and ABZSO2.
Comparative (mean ± SD) serum concentration profiles of albendazole sulphoxide (ABZSO), albendazole sulphone (ABZSO2) and albendazole (ABZ) obtained after ABZ administration as a single oral dose (400 mg) to human volunteers. The insert shows the individual area under the concentration vs. time (AUC 0-LOQ) of ABZSO as an indicator of systemic drug availability.
Table 1.
ABZSO serum pharmacokinetic parameters.
Fig 2.
Urine concentration profile for ABZSO.
Albendazole sulphoxide (ABZSO) mean (±SD) urine concentration vs. time profiles obtained after albendazole (ABZ) administration as a single oral dose (400 mg, GlaxoSmithKline) to human volunteers. The insert shows the Individual area under the concentration vs. time (AUC0-LOQ) of ABZSO after ABZ administration.
Fig 3.
ABZSO systemic exposure in serum and urine.
Comparative albendazole sulphoxide (ABZSO) individual serum and urine area under concentration vs time curve (AUC0-LOQ) obtained from albendazole-treated human volunteers (400 mg, GlaxoSmithKline). The insert shows ABZSO concentrations (mean ± SD) both in serum and urine samples from treated volunteers.
Table 2.
Parameters describing the urinary excretion of ABZSO.
Fig 4.
Comparative ABZSO serum and urine concentrations.
Comparative albendazole sulphoxide (ABZSO) serum and urine concentrations (mean ± SD) obtained from human volunteers at 24 and 48 h post albendazole (ABZ)-treatment (400 mg, GlaxoSmithKline). The straight-line represents the limit of quantification (LOQ) value determined for the used methodology. The insert shows correlation between individual ABZSO concentration in serum and urine samples at 48 h post ABZ treatment. The straight-line represents the best-fit line obtained by linear regression analysis.